Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OXiGENE OXGN

Healthcare Biotechnology
"OxiGene Inc is a biopharmaceutical company. The Company is engaged in the development of vascular disrupting agents, or VDAs, for the treatment of cancer. It is currently developing two clinical stage investigational drugs, both VDAs- CA4P and OXi4503."

Recent & Breaking News (NDAQ:OXGN)

OXiGENE Announces Granting of Orphan Drug Status in Europe for ZYBRESTAT in Ovarian Cancer

Globe Newswire July 18, 2013

Faruqi & Faruqi, LLP Launches An Investigation Against OXiGENE, Inc. (OXGN) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Business Wire June 18, 2013

OXIGENE Announces Publication of Final FACT Study Data in Journal Thyroid Suggest Survival Benefit of ZYBRESTAT(R) in Patients With Anaplastic Thyroid Cancer

Globe Newswire June 10, 2013

OXiGENE Reports First Quarter 2013 Financial Results

Globe Newswire May 6, 2013

OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial

Globe Newswire April 24, 2013

OXiGENE Announces First Quarter 2013 Earnings Conference Call and Webcast

Globe Newswire April 24, 2013

OXiGENE Announces $5 Million Private Placement

Globe Newswire April 11, 2013

Free Research Reports on HBIO, KIOR, NIHD and OXGN Issued by the Paragon Report

Marketwired April 11, 2013

OXiGENE Announces Issuance of Patent for Benzosuberenes, a Novel Anticancer Class of Agents

Troy Schwensen March 20, 2013

OXiGENE Announces Issuance of Patent for Benzosuberenes, a Novel Anticancer Class of Agents

Globe Newswire March 20, 2013

OXiGENE Reports Full Year 2012 Financial Results

Troy Schwensen March 12, 2013

OXiGENE Announces Year-End 2012 Earnings Conference Call and Webcast

Troy Schwensen March 4, 2013

Free Research Reports on ATML, GMCR, OXGN and TDC Issued by the Bedford Report

Marketwired February 8, 2013

Biotech Companies Attractive Targets for Pharmaceutical Companies Looking to Replace Lost Revenues

Marketwired February 8, 2013

OXiGENE Announces ZYBRESTAT(R) Plus Avastin(R) Continues to be Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Ovarian Cancer Trial

Troy Schwensen February 6, 2013

OXiGENE Announces Presentation at BIO CEO Conference on February 12th

Troy Schwensen February 4, 2013

OXiGENE Appoints Dai Chaplin, Ph.D., to Its Board of Directors

Troy Schwensen January 23, 2013

OXiGENE Regains Nasdaq Closing Bid Price Compliance

Troy Schwensen January 16, 2013

The Real Story Behind OXGN, AAMC, BLKB and ROYL

Marketwired December 31, 2012